Earnings 23 Mar 2026: Intrasense SA (ALINS.PA EURONEXT) pre-market outlook

ALINS.PA stock heads into the pre-market session on 19 Mar 2026 with earnings scheduled for 23 Mar 2026. We note the current price at €0.21, a one-day gain of 3.47%, and a market cap of €11,006,359.00. Investors should focus on revenue trends, R&D spending and cash runway, because Intrasense SA operates in Healthcare software and small changes to guidance can move the thinly traded stock.

ALINS.PA stock: earnings calendar and what to watch

Earnings are scheduled for 23 Mar 2026 and will be the immediate price driver for ALINS.PA stock. Management commentary on recurring license revenue, sales into hospitals and AI biomarkers will matter most to investors. Watch guidance, order backlog and any disclosure on cash needs or financing because free cash flow is negative at -€0.12 per share (EPS -0.12).

ALINS.PA stock: price action and technical snapshot

ALINS.PA stock opened today at €0.19 and traded up to €0.21 with volume 54,258.00 shares, near its average volume of 59,867.00. Technicals show RSI 35.26 (near oversold) and Bollinger Bands at 0.27 / 0.23 / 0.20, indicating a compressed range. The 50-day average is €0.24 and the 200-day average is €0.27, which suggests short-term resistance ahead.

ALINS.PA stock: fundamentals and valuation metrics

The balance sheet and margins are the bigger questions for ALINS.PA stock. Revenue per share is €0.06, net income per share is -€0.21, and operating cash flow per share is -€0.09. Price-to-sales is 3.71, PE is -1.74, and current ratio is 0.39, which signals tight liquidity. Year high is €0.43 and year low is €0.19, underlining high historical volatility.

Meyka AI rates and forecast for ALINS.PA stock

Meyka AI rates ALINS.PA with a score out of 100: 62.99 (B) – HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly €0.28, yearly €0.23, and 3-year €0.20 versus the current €0.21, implying a near-term upside of +33.97% to the monthly figure and +9.63% to the yearly figure. Forecasts are model-based projections and not guarantees. For company info see Intrasense website and the firm’s LinkedIn page source.

ALINS.PA stock: risks, catalysts and sector context

Key risks for ALINS.PA stock include cash strain, low current ratio, and negative operating margins which could force dilution. Catalysts are stronger-than-expected SaaS uptake, AI partnerships, or a clear path to profitability. The Healthcare software sector has average ROE near 6.07%, and Intrasense must outperform that peer set to re-rate positively. We note the company spends ~33% of revenue on R&D, a potential growth lever if commercial adoption follows.

ALINS.PA stock: trading considerations and realistic price targets

Given liquidity and volatility, position sizing should be conservative for ALINS.PA stock. Meyka AI uses model targets of €0.28 (short-term) and €0.23 (12 months) as reference points. A reasonable conservative price target for risk-aware traders is €0.20 – €0.28, while upside scenarios assume successful commercialization and reduced cash burn. See the Meyka stock page for live quotes and alerts: ALINS.PA on Meyka.

Final Thoughts

ALINS.PA stock enters the market on 19 Mar 2026 with earnings on 23 Mar 2026 as the immediate catalyst and the stock trading at €0.21. Fundamentals show negative EPS -0.12, low current ratio 0.39, and a market cap of €11,006,359.00, which heighten short-term risk. Meyka AI’s model gives a monthly target of €0.28 (+33.97%) and a 12-month target of €0.23 (+9.63%) versus the current price; these figures reflect scenario-based upside if revenue conversion accelerates. Investors should weigh limited liquidity, potential dilution and sector comparatives before acting. Our view: monitor the 23 Mar 2026 earnings for sales traction and cash commentary, use small position sizes, and revisit targets after management updates. Meyka AI provides this as one data point within its AI-powered market analysis platform; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.